Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Standard Care Control Clear all
Completed Phase 3 Interventional Results available

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

NCT04093024
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 11, 2026, 1:48 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

NCT05758415
View directory record Official record
Conditions
Rotator Cuff Tendinopathy
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
La Mesa, California • Van Nuys, California • Winter Park, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Phase 2Phase 3 Interventional

ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

NCT05070260
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous glenzocimab (ACT017) 1000 mg, Intravenous Placebo
Drug
Lead sponsor
Acticor Biotech
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Bradenton, Florida • St. Petersburg, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 11, 2026, 1:48 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

NCT05624749
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ianalumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
15
States / cities
Anniston, Alabama • La Palma, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Not applicable Interventional

Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients

NCT02923804
View directory record Official record
Conditions
Non Alcoholic Fatty Liver
Interventions
Omega-3, Olive oil
Dietary Supplement
Lead sponsor
Pronova BioPharma
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Hialeah, Florida • Lake Worth, Florida • Lauderdale Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 11, 2026, 1:48 AM EDT
Terminated Not applicable Interventional

A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation

NCT03783884
View directory record Official record
Conditions
Ventilator Induced Diaphragm Dysfunction
Interventions
Lungpacer Diaphragm Pacing Therapy
Device
Lead sponsor
Lungpacer Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
22
States / cities
Stanford, California • Aurora, Colorado • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Phase 3 Interventional

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

NCT02492620
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
Interventions
Ferric Citrate
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 11, 2026, 1:48 AM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
View directory record Official record
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Upland, California • DeBary, Florida • Hollywood, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 11, 2026, 1:48 AM EDT
Recruiting Not applicable Interventional

Implementation of Team Clinic for Type 2 Diabetes (TCT2)

NCT06923046
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Standard of Care, Shared Medical Appointments
Other · Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 18 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 11, 2026, 1:48 AM EDT
Not listed Not applicable Interventional

Trial Comparing SOC +Skin IQ MCM vs SOC for Pressure Ulcer (PU)

NCT02363842
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Skin IQ™ MCM Coverlet, Pressure redistribution surface
Device · Other
Lead sponsor
Arjohuntleigh
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Sep 11, 2026, 1:48 AM EDT
Terminated Phase 3 Interventional

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

NCT05181540
View directory record Official record
Conditions
Hodgkin Lymphoma, Non Hodgkin Lymphoma
Interventions
AB-205, Placebo
Biological · Other
Lead sponsor
Angiocrine Bioscience
Industry
Eligibility
40 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
28
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 11, 2026, 1:48 AM EDT
Active, not recruiting Phase 2 Interventional

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
CAL02, Placebo
Drug
Lead sponsor
Eagle Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Fresno, California • Gainesville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

NCT01583218
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Betrixaban, Enoxaparin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
7,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
75
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Not applicable Interventional Results available

Closed Incision Negative Pressure Therapy vs Standard of Care

NCT03061903
View directory record Official record
Conditions
Wound Complication
Interventions
Prevena, Aquacel
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated

NCT05045183
View directory record Official record
Conditions
Wound Healing
Interventions
SoC Adhesive Bandage, Antibiotic Ointment, Antiseptic Wash, Hydrocolloid Pad
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 11, 2026, 1:48 AM EDT
Recruiting Not applicable Interventional

Clinical Trial Evaluating an Amnion Membrane Allograft Intended for Use in the Management of Non- Healing Venous Leg Ulcers Versus Standard Of Care Alone

NCT06764953
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
E-GRAFT ™, FIBRACOL™
Other · Device
Lead sponsor
Skye Biologics Holdings, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

NCT03737851
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
elezanumab, placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 11, 2026, 1:48 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03689244
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

NCT02926898
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Venous Leg Ulcers

NCT01138436
View directory record Official record
Conditions
Ulcers
Interventions
MEBO Wound Ointment (MEBO), Standard of Care
Drug · Procedure
Lead sponsor
Skingenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Castro Valley, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

NCT03853694
View directory record Official record
Conditions
Elective Cesarean Section, Pain Management
Interventions
50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Stanford, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 11, 2026, 1:48 AM EDT
Terminated Not applicable Interventional

Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

NCT06572839
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Amnio-Maxx
Other
Lead sponsor
Capsicure, LLC
Network
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Athens, Alabama • San Diego, California • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 11, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia

NCT00703937
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose (FCM), Standard Medical Care (SMC) for the treatment of IDA
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 11, 2026, 1:48 AM EDT
Active, not recruiting Phase 3 Interventional

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574
View directory record Official record
Conditions
Lung Cancer, Non-squamous, Non-small Cell
Interventions
zongertinib, pembrolizumab, cisplatin, carboplatin, pemetrexed
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
22
States / cities
Huntsville, Alabama • Bullhead City, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 11, 2026, 1:48 AM EDT